Evidence-Based Medical News

Mode

All Oncology Infectious Disease Neurology Psychiatry Cardiology Diabetes & Endocrinology Pediatrics Allergy & Immunology Rheumatology Primary Care & Family Medicine Gastroenterology Nutrition & Obesity Medicine Orthopedics & Sports Medicine OB/GYN & Women's Health Radiology & Imaging Genetics & Precision Medicine Anesthesiology & Pain Medicine Pulmonology & Critical Care Physical Medicine & Rehab Nephrology Emergency Medicine Urology Ophthalmology Hematology Dermatology Geriatrics & Aging ENT (Otolaryngology) Palliative Care

Research

Clinical Trials Drug Pipeline Weekly Digests

Reference

Conditions Medications

Community

Text Size

Log in / Sign up

Androgenetic alopecia

Subtypes of Androgenetic alopecia

Alopecia Areata 11

13 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for androgenetic alopecia

24 trials tracked for androgenetic alopecia: 4 in phase 3 or 4 and 1 with published results. The most-cited published study has 14 citations.

24Trials tracked

4Phase 3 & 4

0Recruiting

1With published results

Phase distribution

Phase 3 4 Phase 2 5 Phase 1 1 Other / NA 14

Phase 3 Evaluating the Topical Herbal Solution on the Treatment of Male Pattern Hair Loss and Comparison With Minoxidil 5% Completed · 14 cited
Phase 3 Study to Evaluate the Efficacy and Safety of P-3074 Topical Solution in the Treatment of Androgenetic Alopecia Completed
Phase 3 Dutasteride Versus Placebo and Finasteride in Men With Androgenetic Alopecia Completed
Phase 3 Clinical Trial in Females for Female Pattern Hair Loss Completed
Phase 2 A Safety and Efficacy Study of Bimatoprost in Men With Androgenic Alopecia (AGA) Completed
Phase 2 Study of TDM-105795 Following Topical Administration in Male Subjects With Androgenetic Alopecia Completed

Show 18 more trials

Phase 2 Safety and Efficacy Study of Bimatoprost in the Treatment of Men With Androgenic Alopecia Completed
Phase 2 A Study in Male and Female Subjects With Androgenetic Alopecia Treated With ATI-50002 Topical Solution Completed
Phase 2 Topical Bimatoprost Effect on Androgen Dependent Hair Follicles Completed
Phase 1 Safety and Pharmacokinetics Study of New Formulation of Bimatoprost in Patients With Alopecia Completed
N/A Association of Androgenetic Alopecia and Severity of Coronavirus Disease 2019 (COVID-19). Completed
N/A A Novel Approach to Treating Androgenetic Alopecia in Females With Low Level Laser Therapy Completed
N/A Anti-Androgen Treatment for COVID-19 Completed
N/A STYLE -- A Trial of Cell Enriched Adipose For Androgenetic Alopecia Completed
N/A Treatment of Androgenetic Alopecia in Females, 9 Beam Completed
N/A Efficacy Study of a Cosmetic Lotion in the Treatment of Androgenetic Alopecia in Males and Females Completed
N/A Treatment of Androgenic Alopecia in Males Completed
N/A Treatment of Androgenetic Alopecia in Males Completed
N/A Adipose-derived SVF for Treatment of Alopecia Completed
N/A The Effect of Platelet Rich Plasma on Non-scarring Alopecia Completed
N/A Modulated Light Therapy in Participants With Pattern Hair Loss Completed
N/A Computer-Assisted Versus Manual Hair Harvest Comparative Study Completed
N/A DUS on the Prescribing Indications for CPA/EE in 5 European Countries Completed
N/A Treatment of Androgenetic Alopecia in Females, 12 Beam Completed

Showing the 24 most-cited and recently-updated of 24 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found For clinicians

Androgenetic alopecia: what the trials found

Several interventions have demonstrated statistically significant improvements in hair growth metrics for androgenetic alopecia. P-3074 showed a significant increase in the adjusted mean change from baseline in hair growth as assessed by Target Area Hair Count (TAHC) at both 12 weeks and 24 weeks (p < 0.001) ². However, changes in Target Area Hair Width (TAHW) for this intervention did not reach statistical significance (p = 0.322) ².

Minoxidil 5% topical foam demonstrated significant improvements in both Target Area Hair Count and Subject Assessment of Scalp Coverage (p < 0.0001) ³. Finasteride 1mg also showed statistically significant increases in Target Area Hair Count at the vertex at week 24 (p = 0.046) ⁴, with notable improvements observed at the 12-week mark as well.

Bimatoprost Formulation A was evaluated for safety and tolerability; trials indicated no clinically significant ECG findings and a low incidence of increased local scalp tolerability issues ¹⁰. While clinical outcome scores (SSA, IGA, GPR) were recorded for this formulation, they did not reach statistical significance in the primary reported data ⁹.

Recent results — preliminary, needs further review

TDM-105795 (0.0025%) was evaluated in a Phase 2 trial regarding Investigator's Global Assessment (IGA) scores, but results are not yet corroborated.
Bimatoprost Solution 1 showed varied response categories across SSA, IGA, and GPR scales in a Phase 2 study.
Bimatoprost demonstrated mixed results in percent changes for target area total, terminal, and vellus hair counts.

For the clinician treating this condition

P-3074 is associated with significant increases in Target Area Hair Count at the vertex at 12 and 24 weeks.
5% Minoxidil topical foam and 1mg Finasteride are established interventions that significantly increase target area hair counts.
Bimatoprost Formulation A demonstrated a favorable safety profile regarding ECG findings and local scalp tolerability.

AI synthesis of 5 cited trials, updated Jun 27, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

1 2 Next ›

All androgenetic alopecia Articles